1例NK/T细胞淋巴瘤伴糖尿病患者的药学监护 点击下载
论文标题: 1例NK/T细胞淋巴瘤伴糖尿病患者的药学监护
英文标题:
中文摘要: 目的:探讨临床药师在NK/T细胞淋巴瘤(NK/TL)伴糖尿糖患者化疗过程中实施药学监护的模式、方法与作用。方法:临床药师参与1例NK/TL伴糖尿病患者的SMILE方案的化疗,在首次化疗时对化疗过程潜在的风险进行评估,并实施个体化用药监护并提出建议。具体为给予胰岛素注射液4 U,ivgtt控制地塞米松所致血糖值升高;给予碳酸氢钠40 ml,ivgtt,bid碱化尿液,别嘌醇0.1 g,po,tid抑制尿酸形成;给予补液4 000 ml/d预防肾功能衰竭,冲入美司钠0.4 g/次进行尿路保护;对可能出现的过敏反应和骨髓抑制进行监护;对SMILE方案的解救药物亚叶酸钙的使用进行用药教育。结果:医师采纳临床药师建议,患者化疗过程顺利,未出现药品不良反应,用药依从性良好。结论:临床药师参与患者化疗过程,对其潜在的风险进行评估并实施个体化用药监护,可优化患者的药物治疗方案,降低药物治疗过程中的风险,确保用药安全。
英文摘要: OBJECTIVE: To explore the mode, methods and role of clinical pharmacists providing pharmaceutical care for patients with natural killer/T-cell lymphoma (NK/TL) complicated with diabetes.  METHODS: Clinical pharmacists participated in SMILE chemotherapy plan for a NK/TL patients with diabetes mellitus, evaluated potential chemotherapy risk during first chemotherapy, implemented individual medication monitoring and put forward suggestion. It included insulin injection 4 U, ivgtt, to control the increase of blood glucose induced by dexamethasone; sodium bicarbonate 40 ml, ivgtt, bid to alkalize urine; allopurinol 0.1 g, po, tid to inhibit uric acid; fluid infusion 4 000 ml/d to prevent renal failure; mesna 0.4 g/time to protect urinary passage; monitorring potential allergic reaction and arrest of bone marrow; providing medication education on the application of calcium folinate in SMILE chemotherapy regimen. RESULTS: Physicians adopted the suggestions of clinical pharmacist, and chemotherapy was carried out smoothly. No ADR was found, and patients manifested good medication compliance. CONCLUSIONS: Clinical pharmacists participate in chemotherapy, evaluate potential risk and provide individual medication monitoring, which optimize therapy plan, reduce medication risk and guarantee the safety of drug use.
期刊: 2016年第27卷第5期
作者: 游丽娜,姜坤
英文作者: YOU Lina,JIANG Kun
关键字: NK/T细胞淋巴瘤;临床药师;药学监护
KEYWORDS: Natural killer/T-cell lymphoma; Clinical pharmacist; Pharmaceutical care
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!